An Array of Diagnostic Information at Your Fingertips
Quick and reliable identification of drug resistant strains of Mycobacterium tuberculosis (MTB) from bacterial culture or human sputum is challenging. Existing molecular diagnostic (MDx) systems are typically too large for crowded laboratories, require a large investment in capital equipment, are too complex to use without extensive training or do not sample across a broad enough range of resistant strains.
The highly accurate and reliable TruArray MDR-TB test is the first portable, bench-top test to identify resistance to rifampin and isoniazid, using a single, workflow-integrated approach. And, unlike other methods that may take days, weeks or even months to test for drug resistance, TruArray MDR-TB delivers results in a few hours.
Image of a TruArray MDR-TB test result demonstrating how the system
differentiates between rifampin-susceptible and rifampin-resistant MTB.
| Catalog # | Product Name & Description |
|---|---|
| 200-10100 | TruArray MDR-TB test kit for detecting multiple drug resistant M. tuberculosis. Includes primers, buffers and reagents to perform 10 tests. |
| Catalog # | Product Name & Description |
|---|---|
| 100-10000 | TruDiagnosis System for multiplexed molecular diagnosis. Includes the Akonni TruDx 1000 Reader, Akonni TruCycler Satellite Thermal Cycler, and laptop computer with data collection and analysis software. Systems include one year warranty against defective parts. Accepts international AC; 90-264V, 50-60 Hz AC. |
| 300-10100 | TruTip DNA Kit for Mycobacterium tuberculosis (60 LPT) includes tips and buffers required to perform 60 MTB extractions on heat-killed specimens. |
| 300-10101 | TruTip DNA Extraction Kit for Mycobacterium tuberculosis (240 LPT) includes tips and buffers required to perform 240 MTB extractions on heat-killed specimens. |
* All of Akonni Biosystems tests are currently for Research Use Only, and are not for use in diagnostic procedures. Akonni is interacting with the Food & Drug Administration (FDA) in order to develop and prepare pre-market notifications seeking clearance to market these products as diagnostic assays in the U.S.
